جست‌وجوی استاد و پژوهشگر

• Developmental Psychology
• Family Psychology
• Child Mental Health
• +۶ مورد دیگر

Professor Bonamy Oliver is a Professor of Developmental and Family Psychology at University College London's IOE - Faculty of Education and Society, leading the Mental Health, Wellbeing and Education Network. Her research focuses on children’s mental health, family relationships, and behavioral genetics. She developed the ESO observation tool, enabling remote parent-child interaction assessments, now used globally. She holds a prestigious 2023 ACAMH Impact Award and contributes to NICE guidelines. Academic roles include Associate Professor (2020-2024) and promoted to full Professor in 2024. She chairs IOE’s Mental Health and Wellbeing Network and directs NurtureLab. Education: PhD in Psychology and Behavioural Genetics (King’s College London, 2006), postdoctoral training at King’s College, followed by faculty roles at Sussex and Goldsmiths. Collaborations span UCL’s Institute of Mental Health, ICH GOS Mental Health Strategic Initiative, and the Accessible Genetics Consortium. Research interests include genetic influences on child development, intervention efficacy, and bridging academic-practitioner gaps. Recent work emphasizes mindful parenting, sibling dynamics, and resilience mechanisms. Articles (2024–2025) address parent-child relationships, polygenic scores in psychopathology, and cross-cultural studies of household chaos. Awards: ACAMH Impact Award (2023), NICE Guidelines contributor Leadership: Chair of IOE’s Mental Health Network, Director of NurtureLab Key Projects: ESO tool, CoTEDS children-of-twins study Advising and grants include interdisciplinary collaborations on child mental health interventions. Labs/Teams: NurtureLab at UCL, cross-institutional mental health initiatives.

• Genetics of Dyslexia
• Learning Disabilities
• Language Impairment
• +۱۲ مورد دیگر

Jeffrey R. Gruen is Professor of Pediatrics (Neonatology) and of Genetics at Yale School of Medicine, and a faculty member in the Investigative Medicine Program at Yale Graduate School of Arts and Sciences. His research is affiliated with multiple centers including the Yale Center for Genomic Health, Wu Tsai Institute, and the Yale Child Health Research Center. Professor of Pediatrics (Neonatology), Yale School of Medicine Professor of Genetics, Yale School of Medicine Member, Investigative Medicine Program, Yale Graduate School Principal Investigator, Gruen Lab Education: MD, Tulane University, 1981 BS in Chemistry, Tulane University, 1977 Residency in Pediatrics, Yale-New Haven Hospital, 1984 Internship in Pediatrics, Yale-New Haven Hospital, 1982 Dr. Gruen's research centers on the genetic and molecular basis of dyslexia and language impairments. His lab pioneered the mapping of the DYX2 locus on chromosome 6 and discovered the DCDC2 gene, a major contributor to reading disability. His team identified READ1, a transcriptional control element that modulates risk for dyslexia, and demonstrated synergistic interactions between genetic variants in DCDC2 and KIAA0319 . His work integrates human genetics, molecular biology, and neuroimaging to understand the biological mechanisms underlying learning disabilities. He leads the Yale Genes, Reading and Dyslexia (GRaD) Study and the New Haven Lexinome Project, aiming to enable early diagnosis and personalized educational interventions. The recent publications reflect a strong trend in integrating genetic data with cognitive, behavioral, and educational assessments. Key themes include genome-wide association studies of dyslexia, gene-environment interactions (particularly involving phonological awareness and home environment), phenotype harmonization across cohorts, and the application of genetic findings to educational policy and practice. Imaging genetics and the study of comorbid conditions like Sluggish Cognitive Tempo are also prominent. Scientific Awards: Innovative Research Award, Kavli Institute, 2022 Dr. Gruen has served as Principal Investigator on numerous NIH-funded studies, including the GRaD Study, the Pediatric Imaging NeuroGenetics (PING) Study at Yale, and the New Haven Lexinome Project. He mentors a broad network of collaborators across institutions such as the University of Colorado, University of Bristol, and Johns Hopkins. His lab trains researchers in human genetics, molecular techniques, and cognitive phenotyping. He leads the Gruen Lab, which focuses on human genetic studies, molecular genetic mechanisms, imaging genetics, and longitudinal intervention studies. The lab collaborates extensively with national and international research centers and utilizes advanced techniques including GWAS, sequencing, chromatin immunoprecipitation, and MRI-based phenotyping.

Kushal Deyمشاهده پروفایل

استادیار

• Computational Biology
• Genomics
• Machine Learning
• +۵ مورد دیگر

Kushal Dey, PhD, is an Assistant Professor in the Computational and Systems Biology Program at Memorial Sloan Kettering Cancer Center (MSKCC). His research develops machine learning models that integrate genetic, genomic, and epigenomic data (e.g., RNA-seq, ChIP-seq, Perturb-seq, spatial transcriptomics) to decode the causal functional architecture of heritable complex diseases, including immune-related disorders like Alzheimer’s and inflammatory bowel disease, as well as heritable cancers such as breast and prostate cancer.

• Critical Care Neurology
• Electroencephalography (EEG)
• Neuroimaging
• +۸ مورد دیگر

Dr. Jennifer Ahjin Kim is an Assistant Professor in the Department of Neurology at Yale School of Medicine. She specializes in neurocritical care, focusing on quantitative analysis of electroencephalography (EEG) and neuroimaging for early diagnosis and treatment optimization in patients with severe neurologic injuries. Her clinical interests include traumatic brain injury, subarachnoid hemorrhage, stroke, and post-traumatic epilepsy. PhD in Neuroscience, Brown University (2012) MD from Brown University (2012) Neurology Residency, Massachusetts General Hospital/Brigham & Women's Hospital (2016) Neurocritical Care Fellowship, Massachusetts General Hospital/Brigham & Women's Hospital (2019) Dr. Kim’s research integrates multimodal data (EEG, MRI, CT) with machine learning to predict secondary complications after brain injuries. She actively contributes to clinical trials like BOOST3 and ASPIRE, aiming to improve outcomes for patients with traumatic brain injury, stroke, and hemorrhage. Her recent work emphasizes automated detection of epileptiform discharges, predictive modeling for delayed cerebral ischemia, and application of NLP to CT reports. Collaborations include frequent partnerships with Guido Falcone, Lawrence Hirsch, and Emily Gilmore. Dr. Kim leads the Kim Laboratory, which focuses on bedside monitoring technologies and secondary prevention strategies.

• Neuroscience
• Neuroimaging
• Magnetoencephalography (MEG)
• +۷ مورد دیگر

Krish Singh is a Professor and Head of Human Electrophysiology at Cardiff University's School of Psychology. He holds a BSc from Durham University and a PhD from the Open University. As a leader at the Cardiff University Brain Research Imaging Centre (CUBRIC), he drives multimodal neuroimaging research, focusing on MEG/EEG methodologies for clinical and cognitive neuroscience. His work spans epilepsy, schizophrenia, and Alzheimer’s disease, including studies on electrophysiological genetic risk markers. His research bridges physics and neuroscience, emphasizing non-invasive brain imaging (MRI/MEG) to explore neural mechanisms in health and disease. Key interests include: Cortical oscillations and neurophysiological biomarkers Genetic influences on brain networks in psychiatric disorders Multimodal integration of MEG with MRI/PET data Clinical applications in neurodegeneration and epilepsy Publications demonstrate consistent focus on neurophysiology, schizophrenia, Alzheimer’s, and methodological innovations in MEG analysis. Trends include genetic risk modeling, pharmacological modulation of neural oscillations, and longitudinal biomarker discovery. He leads the undergraduate module Introduction to Neuroimaging Methods and Applications , covering MRI, fMRI, EEG/MEG, TMS, and clinical applications. As a supervisor, he supports postgraduate projects in neuroimaging and collaborates internationally via the MEG-UK Partnership to standardize MEG methodologies. He directs research at CUBRIC and collaborates with Cardiff's Neuroscience and Mental Health Innovation Institute, fostering cross-disciplinary studies with medicine and biosciences.

Richard T. Carsonمشاهده پروفایل

استاد

• Environmental Economics
• Contingent Valuation
• Statistical Methods in Genomics
• +۲ مورد دیگر

Richard T. Carson is a Professor in the Department of Economics at the University of California, San Diego, with expertise in environmental valuation and statistical methods. He received his education from UC Berkeley (Ph.D. 1985, M.A. Statistics 1985), George Washington University (M.A. 1980), and Mississippi State University (B.A. 1977). His research focuses on environmental economics, contingent valuation methods, and genomic data analysis. Key areas include non-market valuation of public goods, economic impacts of environmental incidents, and methodological advances in statistical genetics. Analysis of recent publications shows strong emphasis on interdisciplinary approaches combining economics with genomics and public health. Current work explores water resource economics, pandemic responses, and genetic risk modeling. Awards: Best Paper Award, Asia Pacific Bioinformatics Conference CLIO Prize for Atlantic Canada, Canadian Historical Association Dr. Carson has supervised over 300 student theses and dissertations throughout his career and directs research through various academic collaborations.

Ole Andreas Andreassenمشاهده پروفایل

استاد

• Mental Disorders
• Neuropsychiatric Disorders
• Genetics
• +۶ مورد دیگر

Ole Andreas Andreassen is a Professor of Psychiatry and Director of the Centre for Precision Psychiatry at the University of Oslo. He holds a joint appointment as an Attending Psychiatrist (20%) at Oslo University Hospital. His academic career includes leadership roles such as Director of the Centre of Excellence NORMENT (2013–2023) and the KG Jebsen Centre for Psychosis Research (2012–2018). He completed his MD (1993) and PhD (1996) at the University of Bergen, followed by postdoctoral training at Harvard Medical School and Massachusetts General Hospital. Education: MD (1993, University of Bergen), PhD (1996, University of Bergen) Postdoc: Harvard Medical School (1998–2000) Specialist in Psychiatry: Oslo University Hospital (2006) His research focuses on mental and neuropsychiatric disorders, emphasizing genetics, brain imaging, and precision medicine. Key areas include the interplay of genetic and environmental factors in schizophrenia, bipolar disorder, and Alzheimer’s disease. He has pioneered studies on predictive tools and clinical interventions, with a strong emphasis on genomic and neuroimaging biomarkers. His publications span over 10 years, addressing topics like cortical abnormalities in bipolar disorder, genetic overlap between psychiatric conditions, and cannabis use impacts. These works highlight interdisciplinary approaches, blending genetics, neuroimaging, and clinical data. Awards: Brain Council Award (2024), Fridtjof Nansen Award (2023), University of Oslo Research Prize (2020) Leadership: Co-Director of the KG Jebsen Centre for Neurodevelopmental Disorders, ENIGMA Bipolar Working Group Chair, and member of the Psychiatric Genomics Consortium. Andreassen has supervised 42 PhD students and co-supervised numerous postdoctoral researchers. His grants and collaborations span EU-funded initiatives (e.g., CoMorMent, RealMent) and global networks like the Precision Psychiatry consortium. Labs and teams include the Centre for Precision Psychiatry and the Scandinavian Collaboration for Psychiatric Etiology (SCOPE), focusing on translational research and multimodal data integration.

Hua Xuمشاهده پروفایل

استاد

• Clinical Natural Language Processing
• Biomedical Informatics
• Large Language Models for Biomedicine
• +۳ مورد دیگر

Dr. Hua Xu is the Robert T. McCluskey Professor of Biomedical Informatics and Data Science at Yale School of Medicine. He serves as Vice Chair for Research and Development in the Department of Biomedical Informatics and Data Science and as Assistant Dean for Biomedical Informatics at Yale School of Medicine. Dr. Xu leads the Clinical NLP Lab and is Chair of the NLP working group at the Observational Health Data Sciences and Informatics (OHDSI) program. Dr. Xu received his PhD in Biomedical Informatics from Columbia University, an MS in Computer Science from New Jersey Institute of Technology, and a BS in Biochemistry from Nanjing University. Dr. Xu is a renowned researcher in clinical natural language processing (NLP), having developed novel algorithms for important clinical NLP tasks such as entity recognition and relation extraction. His work has been top-ranked in over a dozen international biomedical NLP challenges. He has developed CLAMP, a comprehensive clinical NLP toolkit that has been successfully commercialized and adopted by hundreds of healthcare organizations worldwide. His research focuses on applying NLP technologies to diverse clinical and translational studies to accelerate clinical evidence generation using electronic health records data. Recently, he has been utilizing NLP to harmonize metadata of biomedical digital objects to promote FAIR principles in biomedicine, and his lab is actively working on developing large language models (LLMs) for diverse biomedical applications. Dr. Xu's recent publications demonstrate a clear trend toward leveraging large language models for biomedical applications. His work spans from benchmarking LLMs for clinical NLP tasks to developing specialized architectures like BiomedRAG (retrieval augmented LLMs for biomedicine). His research addresses critical healthcare challenges including adverse event extraction, oncology clinical trial analysis, and EHR-based association studies, showing how NLP can bridge the gap between unstructured clinical text and actionable medical insights. Dr. Xu's lab has achieved top rankings in numerous NLP challenges, including multiple #1 positions in i2b2 Temporal information extraction, SemEval Disease-modifier extraction, BioCREATIVE Chemical-induced disease extraction, and other prestigious competitions. His contributions to clinical NLP have significantly advanced the field's ability to extract meaningful information from complex medical texts. As the leader of the Clinical NLP Lab at Yale, Dr. Xu oversees research that forms a complete ecosystem: developing novel NLP methods, building robust software tools, and applying these technologies to clinical and translational research. His lab's work closes the loop between methodological innovation and practical healthcare applications, ensuring that advances in NLP directly benefit patient care and medical research.

Niklas Mattsson-Carlgrenمشاهده پروفایل

دانشیار

• Alzheimer's Disease
• Neurodegenerative Diseases
• Tau Pathology
• +۷ مورد دیگر

Niklas Mattsson-Carlgren serves as an Associate Professor and Senior Lecturer at Lund University's Faculty of Medicine, Department of Clinical Sciences. He holds multiple significant roles including Deputy Research Team Manager and Principal Investigator for several major research projects. His affiliations extend to the Wallenberg Centre for Molecular Medicine (WCMM), LU Profile Area: Proactive Ageing, and MultiPark: Multidisciplinary Research Focused on Parkinson's Disease. Dr. Mattsson-Carlgren's research primarily focuses on Alzheimer's disease and other neurodegenerative conditions, with additional work on acute brain injuries such as those following cardiac arrest. His expertise spans neurochemistry, including the regulation of pain and sleep. He employs biochemical measurements, neuroimaging, and cognitive testing to study disease processes in vivo across the spectrum from preclinical disease to advanced dementia. His work aims to improve diagnostic and prognostic methods in clinical practice, enhance clinical trial design for novel therapies, and deepen understanding of disease mechanisms. His recent publications demonstrate a strong emphasis on plasma biomarkers for Alzheimer's disease detection and monitoring, with particular focus on tau and amyloid pathology. The research shows increasing integration of machine learning approaches with traditional biomarker analysis, reflecting a trend toward more sophisticated diagnostic tools that combine multiple data sources for improved accuracy in predicting disease progression. As Principal Investigator for multiple significant projects including 'Longitudinal plasma biomarkers, cognitive data and amyloid PET to improve early prevention of Alzheimer's disease' and 'Validation of an MTBR tau immunoassay for CSF and plasma,' he leads substantial research efforts funded by organizations including Familjen Rönströms stiftelse, Eli Lilly and Company, and the Knut and Alice Wallenberg Foundation. He also serves as supervisor for PhD students, notably for 'Studies of induced neuronal cells in Alzheimer's disease.' Dr. Mattsson-Carlgren is actively involved in the neuroscience community, serving on the program committee for Neuroscience Day 2025. His research contributes to UN Sustainable Development Goals related to health and wellbeing. His work has gained significant attention, with multiple papers being picked up by news outlets and referenced across social media platforms including X (Twitter) and Bluesky.

Espen Moldenمشاهده پروفایل

استاد مدعو

• Pharmacology
• Pharmacokinetics
• Pharmacogenetics
• +۴ مورد دیگر

Dr. Espen Molden is an Adjunct Professor at the Department of Pharmacy, University of Oslo, holding a 20% position while serving as Research Manager at the Center for Psychopharmacology, Diakonhjemmet Hospital. He earned his Cand.pharm. degree from the University of Oslo in 1997 and completed his Dr.scient. there in 2003. His primary research focuses on individual variability in drug efficacy and side effects, with particular emphasis on implementing pharmacogenetic knowledge in clinical practice. His research interests span multiple areas of pharmacology, including: Pharmacokinetics and therapeutic drug monitoring Pharmacogenetics (particularly CYP2D6 and CYP2C19) Drug interactions and cytochrome P450 metabolism Clinical applications in psychopharmacology Analysis of his 15 most recent publications (2024-2025) reveals a strong focus on pharmacogenetics applications in clinical settings, particularly in psychopharmacology. His work heavily features therapeutic drug monitoring studies, CYP enzyme polymorphisms, and their clinical implications for antipsychotic and antidepressant treatments. A significant portion of his recent work examines clozapine metabolism, CYP2D6-related pharmacogenetics, and real-world data applications in personalized medicine. His scientific achievements include: Pharmacist of the Year award from the Norwegian Pharmaceutical Association (2006) Extensive publication record in high-impact journals including Nature Genetics, JAMA, and Clinical Pharmacology & Therapeutics Leadership in large collaborative research projects across multiple institutions Dr. Molden actively collaborates with numerous researchers including Professor Torgeir Bruun Wyller at Oslo University Hospital, Professor Anette Hylen Ranhoff at Diakonhjemmet Hospital, and international colleagues from institutions like Karolinska Institutet. His work bridges basic pharmacogenetic research with clinical implementation, particularly in psychiatric medication management.

• Alzheimer's disease
• Neurodegeneration
• Neuroimaging and biomarkers
• +۵ مورد دیگر

P. Murali Doraiswamy, MBBS, FRCP , is Professor of Psychiatry and Professor in Medicine at Duke University School of Medicine, Director of the Neurocognitive Disorders Program, Senior Fellow at the Duke Center for the Study of Aging and Human Development, and holds affiliate faculty appointments with the Duke Center for Applied Genomics & Precision Medicine, the Duke Microbiome Center, and the Duke Initiative for Science & Society. He is a Faculty Network Member of the Duke Institute for Brain Sciences and has advised major agencies including NIH, FDA, WHO, and the World Economic Forum. Research Focus Dr. Doraiswamy leads a multidisciplinary program that integrates advanced neuroimaging, multi-omics, digital therapeutics, and artificial intelligence to understand, predict, and prevent Alzheimer’s disease and related neurodegenerative disorders. His work spans: Development and validation of blood, CSF, imaging, and digital biomarkers for early detection and staging. Clinical trials of novel pharmacological, lifestyle, and digital interventions in mild cognitive impairment (MCI) and Alzheimer’s dementia. Systems-biology approaches combining genomics, metabolomics, lipidomics, and microbiome data to uncover mechanisms of resilience and risk. Policy translation and global mental health initiatives aimed at reducing disparities and improving brain health worldwide. Publications & Impact With more than 400 peer-reviewed publications and continuous federal and industry funding, his research has shaped current diagnostic algorithms and therapeutic pipelines. Recent work (2023-2025) demonstrates accelerated adoption of deep-learning MRI models for amyloid/tau staging, AI-guided companion robots to combat loneliness, and precision nutrition trials leveraging microbiome signatures. Scientific Leadership & Recognition He has chaired the World Economic Forum’s Global Agenda Council on Brain Research and co-chaired innovation advisory councils for large social-impact funds. His findings have been featured by BBC, The New York Times, Scientific American, TIME, NPR, CBS Evening News, Oprah, The Dr Oz Show , and acclaimed documentaries such as (Dis)Honesty: The Truth about Lies and Mysteries of the Brain . Advocacy & Societal Engagement Beyond the laboratory, Dr. Doraiswamy is a leading advocate for increased public and private investment in brain and behavioral research. He serves on multiple charitable boards and co-authored the popular book The Alzheimer’s Action Plan , translating cutting-edge science into practical guidance for patients and families.

• Decision Psychology
• Cognitive Science
• Rationality Models
• +۵ مورد دیگر

Ralph Hertwig is the Director of the Research Department of Adaptive Rationality and Deputy Managing Director of the Max Planck Institute for Human Development in Berlin. He holds honorary professorships at both the Free University of Berlin (since 2016) and Humboldt University of Berlin (since 2013). His research focuses on models of limited and ecological rationality, experience-based decisions, psychology of risk, development of decision-making processes across the lifespan, and evidence-based interventions to increase decision-making and self-control skills (boosting). Hertwig's work bridges cognitive science, psychology, and practical applications for improving decision-making in complex environments. Hertwig's recent publications reveal a strong focus on behavioral interventions against misinformation, risk perception across the lifespan, cross-species comparisons of decision-making, and the development of boosting techniques as alternatives to traditional nudging approaches. His work increasingly addresses digital challenges, misinformation, and democratic discourse in the attention economy. Selected honors: Gottfried Wilhelm Leibniz Prize (2017) Charlotte and Karl Bühler Prize (2006) Fellow, Association for Psychological Science (2011) Member, German National Academy of Sciences Leopoldina Hertwig actively contributes to multiple academic initiatives including the International Max Planck Research School on the Life Course (LIFE), the Max Planck School of Cognition, and the International Max Planck Research School for Computational Methods in Psychiatry and Aging Research (COMP2PSYCH). His keynote speeches worldwide demonstrate the broad impact of his research on decision-making science.

• Myopia Genetics
• Genomic Epidemiology
• Vision Science
• +۳ مورد دیگر

Professor Jeremy Guggenheim is a leading researcher in myopia genetics at Cardiff University's School of Optometry and Vision Sciences. With over two decades of research experience, he has made significant contributions to understanding the genetic and environmental factors contributing to short-sightedness. His work has been instrumental in identifying over four hundred genetic variants associated with myopia susceptibility through international collaborative efforts. His research interests span myopia genetics, genomic epidemiology, and the gene-environment interactions that influence refractive error development. Professor Guggenheim employs advanced genetic techniques including genome-wide association studies, Mendelian randomization, and polygenic risk scoring to unravel the complex etiology of myopia. His work bridges basic science discoveries with clinical applications for early detection and prevention of high myopia. Analysis of his recent publications (2023-2025) reveals a strong focus on genetic risk prediction, environmental modifiers of myopia development, novel treatment mechanisms, and international consensus building for myopia management. His work increasingly incorporates machine learning approaches for disease detection while maintaining a strong foundation in genetic epidemiology. College of Optometrists Biennial Arthur Bennett Prize for Outstanding Research (2012/2013) ARVO Gold Fellow Award (2022) Professor Guggenheim has supervised numerous PhD students throughout his career and currently leads the Investigative Techniques undergraduate module. He serves on editorial boards for Ophthalmic & Physiological Optics, Translational Vision Science & Technology, and as Associate Editor for Investigative Ophthalmology and Visual Science. His research is supported through multiple international collaborations including the Consortium for Refractive Error and Myopia (CREAM) and the UK Biobank Eye and Vision Consortium.

Michael Nothnagelمشاهده پروفایل

استاد

• Statistical Genetics
• Genetic Epidemiology
• Population Genetics
• +۵ مورد دیگر

Michael Nothnagel is a Professor at the University of Cologne, where he leads the Department of Statistical Genetics and Bioinformatics within the Cologne Center for Genomics (CCG). His work spans statistical genetics, genetic epidemiology, and forensic genetics, focusing on methodological development and large-scale genomic data analysis. His research interests encompass theoretical and applied statistical genetics, with emphasis on human genetic diversity, disease etiology, and forensic applications. Key areas include Y-chromosomal phylogeography, genome-wide association studies for complex diseases, development of statistical methods for variant interpretation, and forensic marker optimization. His group leverages next-generation sequencing data and specialized forensic markers to address questions in population history, disease mechanisms, and identification systems. Recent publications reveal a strong focus on computational approaches to genetic analysis, including spatial frequency interpolation for haplogroup mapping, polygenic risk score applications for behavioral traits, and advanced methods for variant classification. His work demonstrates consistent integration of statistical theory with practical applications in medical and forensic genetics, often through international collaborations like the VISAGE Consortium. Nothnagel maintains active involvement in the Cologne Center for Genomics, contributing to seminars and collaborative projects including the upcoming 34th International Genetic Epidemiology Society meeting. His research group operates at the intersection of computational biology and medicine, with particular strengths in handling complex genomic datasets and developing novel analytical frameworks for genetic epidemiology.

• Human Evolutionary Genetics
• Computational Biology
• Genotype/Phenotype Architecture
• +۳ مورد دیگر

Timothy D. O'Connor is an Associate Professor in the Department of Medicine at the University of Maryland School of Medicine, serving as Co-Director for the Program in Health Equity and Population Health (HEPH). His research focuses on the evolutionary and population genetic influences on disease and phenotypic diversity, integrating evolutionary theory with large genomic datasets. He leads the O’Connor Evolutionary Genomics Group, emphasizing collaboration and multi-omics approaches. Education: B.S. Bioinformatics, Brigham Young University (2001-2007) Ph.D. Evolutionary Genetics, University of Cambridge (2007-2011), supported by the Gates Cambridge Scholarship Senior Research Fellow, University of Washington (2010-2013) Research Interests: Dr. O’Connor’s work spans human evolutionary genetics, computational biology, and genetic epidemiology. His lab develops novel algorithms to analyze large genomic datasets, with a focus on New World populations, including studies of Peruvian genomic dynamics, malaria parasite migration, and the evolutionary origins of phenotypic diversity. He emphasizes interdisciplinary collaboration and the application of evolutionary principles to modern biomedical challenges. Grants & Awards: NIH/NIAID R01 (2020-2025): $499,998 for malaria genomic migration studies in Cambodia/Thailand NIH/NIGMS R35 (2019-2024): $299,713 for evolutionary multi-omics research 2021 Faculty Mentoring Award 2019 Teacher of the Year Award Labs & Collaborations: His lab is part of the TOPMed Program, co-leading the Population Genetics Working Group. He also collaborates on projects like the Peruvian Genome Project and the Gynecological Cancer Center of Excellence. His work bridges academia and clinical practice, addressing disparities in genomic medicine through initiatives like the PENGUIN model for patient engagement.